Thursday, May 30, 2013
An international team led by Novartis AG
and the J. Craig Venter Institute has improved the speed and accuracy of seed influenza
virus production for large-scale vaccine manufacture.1 Adoption of
the platform could shave weeks off the time needed to generate vaccine in
response to a pandemic.
One of many steps
Although the synthetic seed virus
production platform provides time savings for one step in vaccine production,
other time-consuming steps, particularly growing seed virus for large-scale
manufacture of vaccine, have a greater impact on the overall response time to a
A. SciBX 6(21);
doi:10.1038/scibx.2013.509 Published online May 30, 2013
1. Dormitzer, P.R. et
al. Sci. Transl. Med.; published online May 15, 2013; doi:10.1126/scitranslmed.3006368
Contact: Philip R. Dormitzer, Novartis Vaccines and Diagnostics,
Cambridge, Mass. e-mail: firstname.lastname@example.org
2. Gibson, D.G. et al.
Nat. Methods 7, 901-903 (2010)
E. et al. Proc. Natl. Acad. Sci. USA 97, 6108-6113 (2000)
4. Osterholm, M.T. et
al. The compelling need for game-changing influenza
vaccines. (CIDRAP, Oct. 15, 2012)
AND INSTITUTIONS MENTIONED
Biomedical Advanced Research and Development Authority, Washington, D.C.
Center for Infectious Disease Research & Policy, Minneapolis, Minn.
Codagenix Inc., Stony Brook, N.Y.
J. Craig Venter Institute, Rockville, Md.
MedImmune LLC, Gaithersburg, Md.
Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
Philipps University of Marburg, Marburg, Germany
Synthetic Genomics Inc., La Jolla, Calif.
University of Minnesota, Minneapolis, Minn.
World Health Organization, Geneva, Switzerland